CorMedix Inc Cash Flow Conversion Efficiency
CorMedix Inc cash flow conversion efficiency. Based on the latest financial reports, CorMedix Inc (CRMD) has a cash flow conversion efficiency ratio of 0.233x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($94.46 Million) by net assets ($405.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CorMedix Inc (2008–2025)
Cash flow conversion efficiency of CorMedix Inc from 2008 to 2025. This chart illustrates how CorMedix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CRMD stock price and chart for real-time trading data and today's change.
CorMedix Inc Cash Flow Conversion Ratio Explained
CorMedix Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CorMedix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CorMedix Inc ranked by their cash flow conversion efficiency. Also see CorMedix Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Objective Corporation Ltd
AU:OCL
|
0.194x |
|
L&C Bio Co. Ltd
KQ:290650
|
0.014x |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
-1.556x |
|
PureTech Health PLC
NASDAQ:PRTC
|
-0.126x |
|
Phat Dat Real Estate Development Corp
VN:PDR
|
-0.055x |
|
Star Gas Partners LP
NYSE:SGU
|
0.304x |
|
Norma Group AG NA O.N.
XETRA:NOEJ
|
0.035x |
|
Bank Artos Indonesia Tbk PT
JK:ARTO
|
0.035x |
Annual Cash Flow Conversion Efficiency for CorMedix Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of CorMedix Inc from 2008 to 2025. Review CorMedix Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $405.31 Million | $175.05 Million | 0.432x | +172.24% |
| 2024-12-31 | $84.66 Million | $-50.61 Million | -0.598x | -9.18% |
| 2023-12-31 | $70.14 Million | $-38.41 Million | -0.548x | -23.79% |
| 2022-12-31 | $55.06 Million | $-24.36 Million | -0.442x | -31.31% |
| 2021-12-31 | $62.80 Million | $-21.16 Million | -0.337x | +32.18% |
| 2020-12-31 | $44.22 Million | $-21.97 Million | -0.497x | +21.96% |
| 2019-12-31 | $23.65 Million | $-15.05 Million | -0.637x | +86.75% |
| 2018-12-31 | $4.93 Million | $-23.70 Million | -4.803x | -20.86% |
| 2017-12-31 | $7.19 Million | $-28.59 Million | -3.974x | -217.97% |
| 2016-12-31 | $17.81 Million | $-22.27 Million | -1.250x | -239.34% |
| 2015-12-31 | $34.01 Million | $-12.53 Million | -0.368x | +78.82% |
| 2014-12-31 | $3.63 Million | $-6.32 Million | -1.739x | -293.32% |
| 2013-12-31 | $-4.02 Million | $-3.62 Million | 0.900x | -81.21% |
| 2012-12-31 | $-475.38K | $-2.28 Million | 4.788x | +194.03% |
| 2011-12-31 | $1.24 Million | $-6.30 Million | -5.092x | -907.15% |
| 2010-12-31 | $7.26 Million | $-3.67 Million | -0.506x | -446.48% |
| 2009-12-31 | $-14.71 Million | $-2.15 Million | 0.146x | -57.32% |
| 2008-12-31 | $-12.03 Million | $-4.11 Million | 0.342x | -- |
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Pi… Read more